Skip to main content
GLMD
NASDAQ Life Sciences

Galmed's New Oral Drug Formulation Boosts Bioavailability by ~500%

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.633
Mkt Cap
$3.929M
52W Low
$0.411
52W High
$2.34
52W Position info
54% above low
Off High info
73% below high
Rel. Volume
Market data snapshot near publication time

GLMD sits 54% above its 52-week low of $0.411.

Summary

Galmed Pharmaceuticals announced highly positive results from its first-in-man pharmacokinetics study of an oral formulation of Aramchol Meglumine (AM). The study demonstrated that the 400mg AM formulation increased bioavailability by approximately 500% compared to the previous Aramchol Free Acid (AA) 300mg formulation. This substantial improvement in bioavailability is a critical positive development for the drug candidate, indicating a potentially more effective and efficient drug profile. For a micro-cap biotech company, such strong early-stage clinical data significantly de-risks the development pathway and is highly material to the investment thesis. This news is distinct from the recent collaboration announcement with Tissue Dynamics. Investors will now closely monitor the progression of Aramchol Meglumine into subsequent clinical trial phases.

At the time of this announcement, GLMD was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.41 to $2.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GLMD - Latest Insights

GLMD
Sep 08, 2026, 6:08 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.30
Real-time Price: $4.66 info
Change: +$0.360 (+8%) info
Market Cap: $4.822M info
GLMD
Sep 02, 2026, 4:20 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $4.66 info
Change: +$0.541 (+13%) info
Market Cap: $4.822M info
GLMD
Aug 19, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.513
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info
GLMD
Aug 17, 2026, 9:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.5145
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info
GLMD
Aug 17, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.5206
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info